Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07010380

Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)

This study tests PTFinder, a dual-camera system that makes parathyroid glands glow on screen by capturing their natural near-infrared autofluorescence. After a thyroid or parathyroid operation, the removed tissue is scanned with PTFinder and then checked again under normal white light. We will measure how fast (seconds) and how accurately the device finds real glands, confirmed by frozen pathology or a rapid PTH strip. About 180 adult patients at three Chinese hospitals will join. The imaging adds only a few minutes and does not change any part of the surgery. We will also record blood calcium and PTH at 1 h, 24 h, and 7 d after surgery to see whether better gland recovery lowers low-calcium risk.Collected images will also be used to train and test a deep-learning model for fully automated parathyroid recognition; model performance metrics constitute secondary outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fujian Medical University Union Hospital

Fuzhou, FJ, 350001, China

Location status: Recruiting

Location contact

Bo Wang Professor, MD

CONTACT

[email protected]

+86 13959123550

Bo Wang, MD

PRINCIPAL_INVESTIGATOR

About this study

Prospective, paired, observational study at three endocrine-surgery centers. For each specimen:

PTFinder scan - stopwatch runs until the first gland is seen; all suspected glands are marked.

White-light exam - second investigator, blinded to device results, inspects the same specimen.

All marked tissue plus a random "negative" sample go to frozen section or rapid PTH strip; discrepancies are settled by permanent histology.

Outcomes

Primary - time to first gland; detection rate per specimen.

Secondary - sensitivity, specificity, PPV, NPV; post-operative PTH and calcium at 1 h, 24 h, 7 d; incidence of hypocalcaemia.

Sample size: 60 specimens per site (total = 180) gives 80 % power to detect a rise in detection rate from 70 % to 90 % (α = 0.05, McNemar).

Analysis: Paired tests for efficiency, mixed-effects models for accuracy and lab values; multiple imputation for missing data.

Safety & Oversight: PTFinder emits low-intensity NIR light only on ex-vivo tissue; no patient exposure. Device is investigational, not under an FDA IDE. Ethics approval obtained from Fujian Medical University Union Hospital IRB (FJMU-IRB-2025-PTF); other sites use the same central IRB agreement. Data are stored in a secure eCRF.

Collected images will also be used to train and test a deep-learning model for fully automated parathyroid recognition; model performance metrics constitute secondary outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • Scheduled for elective total thyroidectomy, hemithyroidectomy, or parathyroidectomy with removal of thyroid/parathyroid tissue.
  • Able and willing to provide written informed consent for participation and specimen imaging.

Exclusion criteria

  • History of neck irradiation or prior neck surgery that may distort parathyroid anatomy.
  • Pregnancy or breastfeeding.
  • Confirmed or suspected parathyroid carcinoma, or thyroid carcinoma requiring en-bloc parathyroid resection.
  • Inability to understand the study procedures or to comply with follow-up.

Treatment and study plan

PTFinder Dual-Channel NIR Autofluorescence Imaging System

Device

Ex vivo, non-contact imaging of resected thyroid/parathyroid specimens; captures near-infrared autofluorescence and overlays it on white-light video to highlight parathyroid glands (2-5 min per specimen).

Offline Machine-Learning Algorithm (PTFinder-AI Beta)

Other

training/validation on de-identified NIR/RGB frames.

Primary outcomes

  1. Detection Rate of Pathology-Confirmed Parathyroid Glands per Specimen (PTFinder)

    Time frame: Intra-operative imaging session (0-5 minutes)

    Proportion of parathyroid glands correctly located by PTFinder divided by the total number of glands confirmed on frozen section or rapid PTH strip. Unit = % (higher = better).

Secondary outcomes

  1. Time to First Parathyroid Gland Identification (PTFinder)

    Time frame: 1 day (Same imaging session)

    Seconds from start of device scanning to first verified gland highlight (stopwatch). Lower value indicates faster localisation.

  2. Sensitivity of PTFinder

    Time frame: 1 day (Same imaging session)

    True-positive glands / (true-positive + false-negative) versus frozen pathology/PTH strip. Unit = %.

  3. Specificity of PTFinder

    Time frame: 1 day (Same imaging session)

    True-negative sites / (true-negative + false-positive). Unit = %.

  4. Serum PTH Level

    Time frame: 1 hour , 24 hours, 7 days post-op

    Mean parathyroid hormone concentration (pg/mL) at each time-point.

  5. Corrected Serum Calcium Level

    Time frame: 1 hour , 24 hours, 7 days post-op

    Mean calcium (mmol/L) adjusted for albumin.

  6. Incidence of Hypocalcaemia

    Time frame: Up to 7 days post-op

    % of participants with corrected calcium <2.0 mmol/L or symptoms requiring supplementation.

Study contacts

Contact information is provided by the study sponsor or research team.

Bo Wang Professor, MD

CONTACT

[email protected]

+86 13959123550

Sponsors and collaborators

Lead sponsor

Bo Wang,MD

Other

Registry information

Official study title

A Multicenter Prospective Paired Observational Study Evaluating the Performance of the PTFinder Dual-Channel Near-Infrared and White-Light Imaging System With AI-Assisted Analysis for Rapid Identification of Parathyroid Glands in Surgical Specimens

Acronym: PTFinder

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
Jun 8, 2025
Registry last updated
Jun 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.